RenovoRx, Inc.
RNXT
$0.86
-$0.03-2.89%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 185.79% | 453.49% | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 185.79% | 453.49% | -- | -- | -- |
| Cost of Revenue | -10.64% | -- | -- | -- | -- |
| Gross Profit | 365.05% | 388.37% | -- | -- | -- |
| SG&A Expenses | 73.14% | 103.00% | 46.69% | 2.01% | 28.88% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.92% | 21.87% | 22.56% | 2.18% | 33.56% |
| Operating Income | -11.54% | -14.82% | -13.15% | 11.73% | -25.61% |
| Income Before Tax | -45.50% | -2.19% | -17.85% | -21.18% | -124.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -45.50% | -2.19% | -17.85% | -21.18% | -124.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -45.50% | -2.19% | -17.85% | -21.18% | -124.91% |
| EBIT | -11.54% | -14.82% | -13.15% | 11.73% | -25.61% |
| EBITDA | -11.55% | -- | -- | -- | -- |
| EPS Basic | -20.10% | 30.02% | 19.78% | 20.34% | -7.08% |
| Normalized Basic EPS | -20.12% | 41.90% | 19.71% | 20.29% | -7.11% |
| EPS Diluted | -20.10% | 30.02% | 19.78% | 20.34% | -7.08% |
| Normalized Diluted EPS | -20.12% | 41.90% | 19.71% | 20.29% | -7.11% |
| Average Basic Shares Outstanding | 21.14% | 46.00% | 46.93% | 52.09% | 110.04% |
| Average Diluted Shares Outstanding | 21.14% | 46.00% | 46.93% | 52.09% | 110.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |